Literature DB >> 35122151

Activating PIK3CA postzygotic mutations in segmental overgrowth of muscles with bone involvement in the body extremities.

Wen Tian1, Liying Sun1, Qi Zhang2, Junhui Zhao1, Yang Guo1, Wenyao Zhong1, Liu Liu3, Katia Meirelles4, Sha Tang2, Jing Zhang2, Yingzhao Huang5,6,7, Yuehan Yin1, Nan Zhang1, Zongxuan Zhao1, Qingyang Li1, Nan Wu5,6,7, Ping Fang2, Fengqi Chang8, Zhihong Wu9,10,11.   

Abstract

Segmental overgrowth of the skeletal muscles with bone involvement in body extremities, predominantly affecting the upper limb, is an extremely rare condition with only 40-50 affected children described clinically. The molecular pathogenesis of this disorder remains largely unclear except for the identification of a somatic PIK3CA mutation in each of the six patients genetically tested, all restricted to upper limbs in the literature. This study aimed to further characterize the molecular defects for patients affected with segmental overgrowth of the skeletal muscles by analyzing a 9-gene panel selected from the PI3K/AKT/mTOR pathway and genes associated with other related conditions. Nineteen unrelated patients were chosen for this study, comprising ten upper limb (nine unilateral and one bilateral) and nine lower limb (eight unilateral and one bilateral) cases with variable bone involvement. In each case, an activating PIK3CA mutation (p.E110del, p.N345K, p.E542K, p.E545K, p.H1047R, or p.H1047L) was identified in the affected muscle tissue with variant allele frequencies ranging from 13.88 to 30.43%, while no mutation was detected in the paired peripheral blood sample, indicating somatic mosaicism. All detected mutations were limited to PIK3CA and were previously reported in other overgrowth syndromes currently categorized under the PIK3CA-Related Overgrowth Spectrum (PROS). Our study provides strong molecular evidence that isolated segmental overgrowth of the skeletal muscle with bone involvement is a subtype of PROS. Our findings expand the PROS clinical presentations with a newly molecularly classified condition and can provide guidance in clinical and molecular diagnosis and treatment for patients with this condition.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Muscular hypertrophy; Next-generation sequencing; Overgrowth syndrome; PIK3CA; Somatic mutations

Mesh:

Substances:

Year:  2022        PMID: 35122151     DOI: 10.1007/s00438-022-01853-x

Source DB:  PubMed          Journal:  Mol Genet Genomics        ISSN: 1617-4623            Impact factor:   3.291


  27 in total

Review 1.  The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism.

Authors:  Jeffrey A Engelman; Ji Luo; Lewis C Cantley
Journal:  Nat Rev Genet       Date:  2006-08       Impact factor: 53.242

2.  Congenital monomelic muscular hypertrophy of the upper extremity.

Authors:  H Jacobus Gilhuis; Oliver T Zöphel; M Lammens; Machiel J Zwarts
Journal:  Neuromuscul Disord       Date:  2009-09-13       Impact factor: 4.296

3.  Molecular Diagnosis of Mosaic Overgrowth Syndromes Using a Custom-Designed Next-Generation Sequencing Panel.

Authors:  Fengqi Chang; Liu Liu; Erica Fang; Guangcheng Zhang; Tiansheng Chen; Kajia Cao; Yanchun Li; Marilyn M Li
Journal:  J Mol Diagn       Date:  2017-05-11       Impact factor: 5.568

Review 4.  Overgrowth Syndromes Caused by Somatic Variants in the Phosphatidylinositol 3-Kinase/AKT/Mammalian Target of Rapamycin Pathway.

Authors:  Gozde Akgumus; Fengqi Chang; Marilyn M Li
Journal:  J Mol Diagn       Date:  2017-05-11       Impact factor: 5.568

Review 5.  Muscle overgrowth of the upper limb in a proximo-distal gradient and concurrent hypoplasia of the index finger.

Authors:  Mohammad M Al-Qattan
Journal:  J Pediatr Orthop       Date:  2014 Oct-Nov       Impact factor: 2.324

6.  Activating PIK3CA somatic mutation in congenital unilateral isolated muscle overgrowth of the upper extremity.

Authors:  Claudia Castiglioni; Enrico Bertini; Paulina Orellana; Cynthia Villarroel; Facundo Las Heras; Daniel Hinzpeter; Paola Paolinelli; Jorge A Bevilacqua; Karin Alvarez
Journal:  Am J Med Genet A       Date:  2014-06-26       Impact factor: 2.802

7.  COSMIC: exploring the world's knowledge of somatic mutations in human cancer.

Authors:  Simon A Forbes; David Beare; Prasad Gunasekaran; Kenric Leung; Nidhi Bindal; Harry Boutselakis; Minjie Ding; Sally Bamford; Charlotte Cole; Sari Ward; Chai Yin Kok; Mingming Jia; Tisham De; Jon W Teague; Michael R Stratton; Ultan McDermott; Peter J Campbell
Journal:  Nucleic Acids Res       Date:  2014-10-29       Impact factor: 16.971

8.  Upper limb muscle overgrowth with hypoplasia of the index finger: a new over-growth syndrome caused by the somatic PIK3CA mutation c.3140A>G.

Authors:  Mohammad M Al-Qattan; Ali Hadadi; Abdullah M Al-Thunayan; Ahmed A Eldali; Mohammed A AlBalwi
Journal:  BMC Med Genet       Date:  2018-09-04       Impact factor: 2.103

9.  Early activating somatic PIK3CA mutations promote ectopic muscle development and upper limb overgrowth.

Authors:  Sofia Frisk; Fulya Taylan; Izabela Blaszczyk; Inger Nennesmo; Göran Annerén; Bettina Herm; Eva-Lena Stattin; Vasilios Zachariadis; Anna Lindstrand; Bianca Tesi; Tobias Laurell; Ann Nordgren
Journal:  Clin Genet       Date:  2019-05-09       Impact factor: 4.438

10.  Oncogenic mutations mimic and enhance dynamic events in the natural activation of phosphoinositide 3-kinase p110α (PIK3CA).

Authors:  John E Burke; Olga Perisic; Glenn R Masson; Oscar Vadas; Roger L Williams
Journal:  Proc Natl Acad Sci U S A       Date:  2012-09-04       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.